The
United Kingdom Lung Cancer Therapeutics Market is anticipated to grow
significantly in the forecast period, 2024-2028. Lung cancer continues to be a
significant health concern in the United Kingdom, posing substantial challenges
for patients, healthcare providers, and researchers alike. However,
advancements in lung cancer therapeutics have paved the way for improved
treatment outcomes and a better quality of life for affected individuals. The
United Kingdom has a robust healthcare system that prioritizes cancer care,
including lung cancer. Lung cancer remains one of the most common types of
cancer in the United Kingdom, with both smoking-related and non-smoking-related
cases contributing to its prevalence.
Unchecked
cell division in the lungs is what causes the condition known as lung cancer.
Cells naturally divide and create additional copies of themselves. However,
occasionally they experience modifications (mutations) that lead them to
continue producing more of themselves when they shouldn't. The uncontrolled
division of damaged cells results in tissue tumors, which eventually prevent
organs from functioning properly. The term "lung cancer" refers to
cancers that begin in the lungs, typically in the alveoli or small air sacs
(bronchi or bronchioles). Cancers that begin elsewhere and spread to the lungs
are typically given names based on where they originate.
One
of the most significant developments in lung cancer therapeutics has been the
emergence of targeted therapies. These treatments are designed to target
specific molecular alterations in cancer cells, allowing for more precise and
personalized treatment approaches. The United Kingdom has witnessed notable progress
in this area, with several targeted therapies gaining approval and becoming
available for patients.
Immunotherapy
has revolutionized the landscape of lung cancer treatment in recent years. This
innovative approach harnesses the power of the immune system to combat cancer
cells. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have
demonstrated remarkable efficacy in lung cancer patients, particularly those
with advanced or metastatic disease. The availability and utilization of immunotherapies
in the United Kingdom have significantly improved treatment options and
outcomes for patients, thus augmenting the growth of the United Kingdom Lung
Cancer Therapeutics Market.
Early
detection plays a crucial role in improving lung cancer survival rates. The
United Kingdom has implemented various screening programs and initiatives aimed
at identifying lung cancer at earlier stages when it is more treatable. The
National Health Service (NHS) provides low-dose computed tomography (CT) scans
for high-risk individuals, such as long-term smokers, to facilitate early
detection and timely intervention.
According
to the Office for National Statistics, the cost of healthcare in the UK was
estimated to be around USD350.83 billion in 2022, a rise in nominal terms of
0.7% over 2021.
Changing Lifestyle will spur the demand for Lung Cancer
Therapeutics
The United Kingdom is grappling with a significant
burden of lung cancer, a devastating disease that claims numerous lives each
year. According to the International Agency for Research on Cancer, 51,983
new cases of lung cancer were reported in the United Kingdom in 2020,
accounting for 11.8% of the total new cancer cases, which is 457,960. While
multiple factors contribute to the development of lung cancer, the prevalence
of an unhealthy lifestyle stands out as a major driver. Tobacco smoking remains
the primary cause of lung cancer. Despite significant anti-smoking efforts,
smoking rates in the UK remain a concern. Although there has been a decline in
smoking prevalence over the years, a considerable number of individuals
continue to smoke, increasing their susceptibility to developing lung cancer.
The addiction to tobacco necessitates the need for effective lung cancer
therapeutics to combat the disease, which is expected to propel the growth of
the United Kingdom Lung Cancer Therapeutics Market.
Unhealthy eating habits and obesity also play a role in
the development of lung cancer. Consuming a diet lacking in fruits and
vegetables, high in processed foods, and rich in unhealthy fats can lead to
chronic inflammation, compromised immune function, and increased cancer risk.
The UK's high rates of obesity further exacerbate the problem, as excess body
weight is associated with an elevated risk of lung cancer. The link between
diet, obesity, and lung cancer underscores the need for therapeutics to manage
and treat the disease. According to NHS Digital, 25.9% of adults in England
are obese, and a further 37.9% are overweight but not obese. Obesity is usually
defined as having a body mass index (BMI) of 30 or above.
While lifestyle choices play a significant role in lung
cancer development, environmental factors cannot be overlooked. Exposure to
secondhand smoke, air pollution, occupational hazards, and radon gas can all
contribute to an increased risk of lung cancer. Efforts to minimize these
environmental risks are essential, but lung cancer therapeutics continue to be
in demand due to the lingering effects of past exposures and the complexities
of treatment, leading to the expansion of the United Kingdom Lung Cancer
Therapeutics Market.
Download Free Sample Reports
Expanding Advanced Radiation Techniques Revolutionize the United
Kingdom Lung Cancer Therapeutics Market
Lung cancer remains a
significant health challenge, accounting for a substantial number of
cancer-related deaths globally. In the United Kingdom, the battle against lung
cancer has seen remarkable progress, particularly with the advent of advanced
radiation techniques. These cutting-edge therapies have revolutionized the
field of lung cancer therapeutics, offering new hope and improved outcomes for
patients.
Stereotactic Body
Radiotherapy, also known as SBRT, has emerged as a game-changer in the
treatment of lung cancer. This highly precise radiation therapy delivers
focused, high-dose radiation to the tumor while minimizing exposure to healthy
surrounding tissues. SBRT is particularly effective for early-stage lung cancer
patients who are not suitable candidates for surgery. Its shorter treatment
duration, typically completed within a week, makes it an attractive alternative
to conventional radiation therapy.
Furthermore,
Image-Guided Radiation Therapy (IGRT) has significantly improved the accuracy
of radiation delivery in lung cancer treatment. By utilizing advanced imaging
techniques such as CT scans or MRI, IGRT enables precise targeting of tumors,
accounting for any positional changes that may occur during treatment. The
ability to track tumor movement and adjust radiation delivery accordingly
enhances therapeutic efficacy while minimizing damage to healthy lung tissue,
leading to the growth of the United Kingdom Lung Cancer Therapeutics Market.
Additionally, Adaptive
Radiation Therapy (ART) has transformed the landscape of lung cancer treatment
by dynamically adjusting radiation doses based on real-time imaging and
patient-specific anatomical changes. Lung tumors can change shape, size, and
position over the course of treatment, making ART invaluable in optimizing
radiation delivery. By adapting treatment plans to individual patients, ART
ensures optimal tumor coverage while minimizing radiation exposure to healthy
lung tissue.
The introduction of advanced
radiation techniques has had a profound impact on the United Kingdom Lung
Cancer Therapeutics Market. These innovative therapies have expanded treatment
options, improved patient outcomes, and enhanced the quality of life for lung
cancer patients. The reduced treatment duration, enhanced accuracy, and
minimized side effects associated with advanced radiation techniques have made
them increasingly popular choices among healthcare providers and patients
alike. Consequently, the demand for advanced radiation equipment, including
linear accelerators, proton therapy machines, and imaging systems, has surged
in the United Kingdom, stimulating market growth and attracting investments
from both public and private sectors, which is expected to propel the growth of
the United Kingdom Lung Cancer Therapeutics Market.
According to the
International Trade Administration, the medical technology market in the UK has an annual revenue of
about USD30 billion. It has a solid basis made up primarily of small to
medium-sized businesses spread out over the nation, with hubs of activity in
places like the Southeast of England and the Midlands.
Recent Developments
- In May 2023, AstraZeneca
(AZN.L) announced the positive result for the clinical trial of the cancer
medicine Tagrisso. In a late-stage experiment, the medicine Tagrisso from
AstraZeneca combined with chemotherapy was effective in treating patients
with a particular kind of lung cancer. Patients receiving Tagrisso in the
first-line scenario may be given a new therapy option that may allow them
to live longer without their disease getting worse.
Mergers and Collaborations
- In
May 2023, Pfizer and Thermo Fisher Scientific Inc. (NYSE: TMO) announced
they have entered into a collaboration agreement to help increase local
access to next-generation sequencing (NGS)-based testing for patients with
lung and breast cancer. Access to nearby NGS testing can facilitate a
quicker analysis of related genes, enabling medical professionals to
choose the best course of treatment for that specific patient.
Market Segmentation
United Kingdom Lung
Cancer Therapeutics Market is segmented into Cancer Cell Type, Treatment,
Region and Competitive Landscape. Based on Cancer Cell Type, the United Kingdom
Lung Cancer Therapeutics Market is divided into Non-small Cell Lung Cancer
(NSCLC) and Small Cell Lung Cancer (SCLC). Based on Treatment, the market is
categorized into Chemotherapy, Radiation Therapy, Immunotherapy, Targeted
Therapy and Other Treatments. Based on Region, the United Kingdom Lung Cancer
Therapeutics Market is segmented into Scotland, South-East, London, South-West,
East-Anglia, Yorkshire & Humberside, and East Midlands.
Company Profiles
Johnson
& Johnson, Boehringer Ingelheim International GmbH., Novartis AG, Amgen Inc,
Bayer AG, AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Merck
& Co, GlaxoSmithKline plc are some of the key players of United Kingdom Lung
Cancer Therapeutics market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million and CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast,
company shares, competitive landscape, growth factors, and trends
|
|
Segments covered
|
Cancer Cell Type
Treatment
Region
|
|
Country scope
|
Scotland,
South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and
East Midlands
|
|
Key companies profiled
|
Johnson
& Johnson, Boehringer Ingelheim International GmbH., Novartis AG, Amgen
Inc, Bayer AG, AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd.,
Merck & Co, GlaxoSmithKline plc
|
|
Customization scope
|
10% free report customization with purchase.
Addition or alteration to country, regional & segment scope.
|
|
Pricing and purchase
options
|
Avail customized
purchase options to meet your exact research needs.
|
|
Delivery Format
|
PDF
and Excel through Email (We can also provide the editable version of the
report in PPT/Word format on special request)
|
Report Scope:
In this report, United Kingdom Lung Cancer Therapeutics
Market has been segmented into the following categories, in addition to the
industry trends, which have also been detailed below:
- United Kingdom Lung
Cancer Therapeutics Market, By Cancer Cell Type:
- Non-small Cell
Lung Cancer (NSCLC)
- Small Cell Lung
Cancer (SCLC)
- United Kingdom Lung
Cancer Therapeutics Market, By Treatment:
- Chemotherapy
- Radiation Therapy
- Immunotherapy
- Targeted Therapy
- Other Treatments
- United Kingdom Lung
Cancer Therapeutics Market, By Region:
- Scotland
- South-East
- London
- South-West
- East-Anglia
- Yorkshire &
Humberside
- East Midlands
Competitive landscape
Company Profiles: Detailed analysis of the major companies in United
Kingdom Lung Cancer Therapeutics market.
Available Customizations:
With the given market data, TechSci Research offers customizations
according to a company’s specific needs. The following customization options are
available for the report:
Company
Information
- Detailed analysis
and profiling of additional market players (up to five).
United Kingdom Lung Cancer Therapeutics
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected].